Close

Neurotrope (NTRP) Comments on Results from Lilly's (LLY) Solanezumab Phase 3 in Alzheimer's disease

Go back to Neurotrope (NTRP) Comments on Results from Lilly's (LLY) Solanezumab Phase 3 in Alzheimer's disease